Skip to content

Released Aug 6, 2020, after the close

10-Q filed Aug 7, 2020, 38 days after period end · 0001162194-20-000093

Q2 2020 · 10-Q
Revenue$26.06M−7.6% vs Q2 2019−5.6% vs Q1 2020
Net Income-$13.02MN/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.18N/M vs Q2 2019N/M vs Q1 2020
Gross Profit$11,825,000−23.0%
Operating Income-$13,726,000N/M
Operating Cash Flowderived-$2,790,000N/M
Free Cash Flowderived-$3,431,000N/M
Margins · derived
Gross margin45.4%−9.1 pt vs Q2 2019
Operating margin-52.7%−0.8 pt vs Q2 2019
Net margin-49.9%−1.2 pt vs Q2 2019

What the release said

The release

Same quarter

MetricQ2 2020Q2 2019Q2 2018Q2 2017
Revenue$26.06M$28.20M$26.43M$23.91M
Net Income-$13.02M-$13.75M-$16.24M-$16.93M
EPS Diluted-$0.18-$0.20-$0.42-$0.58

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR